BioPharma Resources

Drug Trial Radar · NCT07856420

A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment and an Open-label Long-term Extension Treatment With JNJ-99245354 (ITI-1284)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

705

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Sep 20, 2030

Study completion Sep 28, 2030

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder (GAD; a mental health condition defined by uncontrollable, and excessive worry about everyday events for a long period of time).

Conditions

  • Generalized Anxiety Disorder

Interventions

  • JNJ-99245354Drug

    JNJ-99245354 will be administered sublingually.

  • PlaceboDrug

    Placebo will be administered sublingually.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to End of Week 6 in Hamilton Anxiety Rating (HAM-A) Scale Total ScoreTime frame: Baseline, Week 6

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Inland Psychiatric Medical Group Inc

    Temecula, California · Recruiting

  • Nuovida Research Center

    Miami, Florida · Recruiting

  • Voltaire Clinical Research

    Springfield, Massachusetts · Recruiting

  • Fieve Clinical Research Inc

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.